Earnings Call Summary | Cardiff Oncology(CRDF.US) Q1 2023 Earnings Conference
Earnings Call Summary | Cardiff Oncology(CRDF.US) Q1 2023 Earnings Conference
The following is a summary of the Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript:
以下是加的夫肿瘤学公司（CRDF）2023年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Cardiff Oncology reported a total of $67.2 million in cash and short-term investments as of March 31, 2024.
The company's cash burn in Q1 2024 was $7.7 million, projecting sufficient funds to support the company's operations until the third quarter of 2025.
加的夫肿瘤学报告称，截至2024年3月31日，现金和短期投资总额为6,720万美元。
该公司在2024年第一季度的现金消耗为770万美元，预计在2025年第三季度之前有足够的资金支持公司的运营。
Business Progress:
业务进展：
Cardiff Oncology has made notable progress in its CRDF-004 trial for RAS mutated metastatic colorectal cancer (mCRC).
The company expects data readouts from the trial in Q3/Q4 2024, and plans to increase its activated clinical trial sites to 35.
The recent presentation at the American Association for Cancer research included promising data for their oncology drug, onvansertib, in various cancers.
The company is considering further clinical trials in RAS wild type mCRC and is exploring treatments for ovarian cancer.
加的夫肿瘤学在 RAS 突变转移性结直肠癌 (mCRC) 的 CRDF-004 试验中取得了显著进展。
该公司预计，该试验的数据将在2024年第三季度/第四季度公布，并计划将其激活的临床试验地点增加到35个。
美国癌症研究协会最近发表的演讲包括其肿瘤药物onvansertib在各种癌症中的前景数据。
该公司正在考虑对RAS野生型mCRC进行进一步的临床试验，并正在探索卵巢癌的治疗方法。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。